Navigation Links
Doubling down against diabetes

This press release is available in German.

A collaboration between scientists in Munich, Germany and Bloomington, USA may have overcome one of the major challenges drug makers have struggled with for years: Delivering powerful nuclear hormones to specific tissues, while keeping them away from others.

The teams led by physician Matthias Tschp (Helmholtz Zentrum Mnchen, and Technische Universitt Mnchen) and chemist Richard DiMarchi (Indiana University) used natural gut peptides targeting cell membrane receptors and engineered them to carry small steroids known to act at the cell nucleus. DiMarchi and Tschp hoped that such "turbo-charged" hormone hybrids would only deliver their steroid inside cells, where their specific peptide receptor was expressed at the surface.

Both teams had been working together for years to discover new ways to treat obesity and diabetes. They therefore started out with the gut hormone glucagon-like peptide-1, which is known to act at pancreas and brain cells to improve insulin secretion, blood glucose, and body weight. They engineered these peptides to reversibly bind the female sex steroid, estrogen, which is also known to confer powerful metabolic benefits at some of the same target cells. In the past, pharmacologists had been unable to utilize such benefits as high doses of systemic estrogen can also powerfully affect reproductive organs and increase cancer risk.

Using their GLP-1/estrogen-conjugates however, DiMarchi and Tschp found that they were able to multiply metabolic benefits in mice, without apparent side effects on estrogen-sensitive reproductive organs such as the uterus. They also found no impact of their "turbo-charged" gut peptides on growth of estrogen-sensitive tumors. Genetic studies at the same time however uncovered clear estrogen effects in pancreas and brain tissue of mice treated with the new combination drug candidate, indicating that the collaborating teams had indeed succeeded with targeted delivery of steroids.

"Our novel GLP-1/estrogen molecules seem to outperform more traditional therapeutics in mouse models of obesity and type 2 diabetes" says Brian Finan, scientist at the Helmholtz Zentrum Mnchen and first author of the study published online in the journal Nature Medicine. "What we are even more excited about" he adds "is the opportunity to use targeted steroid hormone for other diseases, where side effects had prevented therapeutic use in the past. "There is still a lot we don't know about the mechanistic details," cautions Matthias Tschp, director of the Helmholtz Institute for Diabetes and Obesity "but if they proof safe enough for clinical use, these molecules could offer transformative potential."


Contact: Tina Heun-Rattei
Technische Universitaet Muenchen

Related medicine news :

1. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
2. Scientists identify major source of cells defense against oxidative stress
3. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
4. Will women use microbicides to protect themselves against HIV?
5. Vitamin E in diet protects against many cancers
6. Lower-Dose Radioiodine Effective Against Thyroid Cancer
7. Study identifies possible protective blood factors against Type 2 diabetes
8. Stem Cell Study Shows Promising Results Against Heart Failure
9. Blood pressure drugs dont protect against colorectal cancer
10. CNIO scientists successfully test the first gene therapy against aging-associated decline
11. Vitamin D + TB vaccine: Allies in fight against bladder cancer?
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... , ... Smiles by Stevens is pleased to announce the addition ... many patients are aware of the benefits of Botox® in the treatment of moderate ... with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... MELVILLE, N.Y. , Nov. 25, 2015  Henry ... products and services to office-based dental, medical and animal ... Dental (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion ... industry,s broadest array of open solutions designed to help ... Click here for a schedule of ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Trovagene, Inc. ... diagnostics, today announced that Chief Executive Officer Antonius Schuh, ... the 27 th Annual Piper Jaffray Healthcare Conference. ... at the New York Palace Hotel in ... at 1:30 p.m. EST. Mr. Schuh will be available ...
(Date:11/25/2015)... International plc (NASDAQ: ENDP ) (TSX: ENL) today announced ... discuss corporate updates at the 27 th Annual Piper ... on Wednesday, December 2, 2015 at 1 p.m. ET. ... the link to the event. Participants should allow approximately 10 ... site and download any streaming media software needed to listen ...
Breaking Medicine Technology: